Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | STS | P08842 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.47 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.47 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30335739 | 1.00 | MEN1 (0.60) | MEN1KMT2APOLBSTSLMNA | |
| SCHEMBL222916 | 0.87 | LMNA (0.66) | MEN1KMT2APOLBSTSLMNA | |
| SCHEMBL955402 | 0.83 | NR1H4 (0.55) | MEN1KMT2APOLBSTSLMNA | |
| SCHEMBL3151354 | 0.81 | POLB (0.61) | MEN1KMT2APOLBLMNATP53 | |
| SCHEMBL4439802 | 0.81 | POLB (0.57) | MEN1KMT2APOLBSTSLMNA | |
| SCHEMBL1512358 | 0.80 | MEN1 (0.63) | MEN1KMT2APOLBSTSSMARCA2 | |
| SCHEMBL22405885 | 0.80 | POLB (0.56) | MEN1KMT2APOLBSTSLMNA | |
| SCHEMBL23407007 | 0.79 | LMNA (0.54) | KMT2ALMNATP53ALOX15TSHR | |
| SCHEMBL23434765 | 0.79 | VEGFA (0.57) | MEN1KMT2ASTSTSHRALDH1A1 | |
| SCHEMBL6366988 | 0.79 | KDM4E (0.53) | MEN1KMT2APOLBLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163454-A1 | SMALL MOLECULE INHIBITORS OF EBOLA AND LASSA FEVER VIRUSES AND METHODS OF USE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163454-A1 | SMALL MOLECULE INHIBITORS OF EBOLA AND LASSA FEVER VIRUSES AND METHODS OF USE | CCR8, RPS8, HDHD5 | MEN1 2622/4885KMT2A 2269/4885POLB 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.